Dr. Reddy's Laboratories (DB:RDDA) - Stock Price, News & Analysis

RDDA Stock Overview

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.

About the company

RDDA fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	5/6
Financial Health	6/6
Dividends	4/6

Rewards

Price-To-Earnings ratio (19x) is below the Pharmaceuticals industry average (25.4x)

Earnings are forecast to grow 2.28% per year

Earnings grew by 43.6% over the past year

Trading at good value compared to peers and industry

Risk Analysis

RDDA passed our risk checks.

Dr. Reddy's Laboratories Limited Competitors

Dermapharm Holding

XTRA:DMP

€1.7b

Merck KGaA

XTRA:MRK

€63.8b

PharmaSGP Holding

XTRA:PSG

€264.0m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of all time highs, changes and price drops for Dr. Reddy's Laboratories
Historical stock prices
Current Share Price	₹66.00
52 Week High	₹72.50
52 Week Low	₹49.00
Beta	0.34
1 Month Change	-4.35%
3 Month Change	7.32%
1 Year Change	21.10%
3 Year Change	10.92%
5 Year Change	77.42%
Change since IPO	130.53%

Recent updates

Shareholder Returns

	RDDA	DE Pharmaceuticals	DE Market
7D	-1.5%	-3.3%	-1.5%
1Y	21.1%	-30.8%	0.9%

Return vs Industry: RDDA exceeded the German Pharmaceuticals industry which returned -31.3% over the past year.

Return vs Market: RDDA exceeded the German Market which returned -0.4% over the past year.

Price Volatility

Is RDDA's price volatile compared to industry and market?
RDDA volatility
RDDA Average Weekly Movement	4.5%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: RDDA has not had significant price volatility in the past 3 months.

Volatility Over Time: RDDA's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1984	25,863	Erez Israeli	www.drreddys.com

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.

Dr. Reddy's Laboratories Limited Fundamentals Summary

How do Dr. Reddy's Laboratories's earnings and revenue compare to its market cap?
RDDA fundamental statistics
Market cap	€11.15b
Earnings (TTM)	€586.79m
Revenue (TTM)	€3.05b

19.0x

P/E Ratio

3.7x

P/S Ratio

Is RDDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RDDA income statement (TTM)
Revenue	₹271.30b
Cost of Revenue	₹113.18b
Gross Profit	₹158.12b
Other Expenses	₹105.92b
Earnings	₹52.21b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 07, 2024

Earnings per share (EPS)	313.51
Gross Margin	58.28%
Net Profit Margin	19.24%
Debt/Equity Ratio	6.0%

How did RDDA perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

13%

Payout Ratio

RDDA Stock Overview

Rewards

Risk Analysis

Dr. Reddy's Laboratories Limited Competitors

XTRA:DMP

€1.7b

XTRA:MRK

€63.8b

XTRA:PSG

€264.0m

DB:2FJ0

€92.8m

Price History & Performance

Recent News & Updates

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Recent updates

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market

Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2022

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jun 29, 2022

Dr. Reddy's Laboratories Limited Launches Posaconazole Delayed-Release Tablets in the U.S. Market

Torrent, JB Chemicals Reportedly in Final Race to Acquire Curatio Healthcare

Dr. Reddy's Laboratories Limited Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Alium JSC entered into agreement to acquire Two anti-bacterial brand Ciprolet and Levolet from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT Vials in the U.S. Market

Dr. Reddy's Laboratories Limited Announces DCGI Approval to the Single-Shot Sputnik Light Vaccine in India

Dr. Reddy's Laboratories Limited (BSE:500124) agreed to acquire Nimbus Health GmbH.